Is TB-500 Legal? Global Status Guide
Category: Healing · Tracked in 158 countries
23
Legal1
Research Only126
Grey Area3
Prescription5
BannedCan You Buy TB-500?
Whether you can buy TB-500 depends on your country. It is legal to purchase in 23 countries, including Jamaica, Dominican Republic, Bahamas, Trinidad and Tobago, Barbados, Cayman Islands, Aruba, Curacao, and 15 more. A prescription is required in 3 countries, including Australia, United Arab Emirates, New Zealand. It falls into a legal grey area in 126 countries (United States, Canada, Germany, France, Netherlands, Sweden, Norway, Denmark, and 118 more), where it may be available for research but not for human use. It is banned in 5 countries: Cuba, China, Singapore, Saudi Arabia, Qatar.
Traveling with TB-500
Traveling internationally with TB-500 requires understanding local laws at your destination. Do not carry TB-500 into countries where it is banned (Cuba, China, Singapore, Saudi Arabia, Qatar) — you could face serious legal consequences. In countries requiring a prescription (Australia, United Arab Emirates, New Zealand), carry a valid prescription or doctor's letter. Always declare pharmaceutical products at customs and check the latest regulations before traveling.
Need to calculate your TB-500 dosage? Use the TB-500 reconstitution calculator on peptide.locker
TB-500 Legal Status by Country (158)
| Country | Status | Rx Required | Schedule | Detail |
|---|---|---|---|---|
| Anguilla | Legal | No | Not Scheduled | Same. Not scheduled under local Drugs Act. De facto unregulated. |
| Antigua and Barbuda | Legal | No | Not Scheduled | Same. Not specifically regulated. |
| Aruba | Legal | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Bahamas | Legal | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Barbados | Legal | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| British Virgin Islands | Legal | No | Not Scheduled | Same. Not scheduled under local Drugs Act. De facto unregulated. |
| Cayman Islands | Legal | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Costa Rica | Legal | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Curacao | Legal | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Dominica | Legal | No | Not Scheduled | Same. Not specifically regulated. |
| Dominican Republic | Legal | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Grenada | Legal | No | Not Scheduled | Same. Not specifically regulated. |
| Jamaica | Legal | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Montserrat | Legal | No | Not Scheduled | Same. Not scheduled under local Drugs Act. De facto unregulated. |
| Papua New Guinea | Legal | No | Not Scheduled | Not specifically regulated. Same framework as BPC-157. No local peptide market or enforcement infrastructure. |
| Samoa | Legal | No | Not Scheduled | Not regulated. Same minimal framework as BPC-157. |
| St Kitts and Nevis | Legal | No | Not Scheduled | Same. Not specifically regulated. |
| St Lucia | Legal | No | Not Scheduled | Same. Not specifically regulated. |
| St Vincent and the Grenadines | Legal | No | Not Scheduled | Same. Not specifically regulated. |
| Tonga | Legal | No | Not Scheduled | Not regulated. Same minimal framework. |
| Trinidad and Tobago | Legal | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Turks and Caicos | Legal | No | Not Scheduled | Same. Not scheduled under local Drugs Act. De facto unregulated. |
| Vanuatu | Legal | No | Not Scheduled | Not regulated. Same minimal framework as BPC-157. |
| United Kingdom | Research Only | No | Not Scheduled | Same status as BPC-157. Not controlled. Legal for research purchase. Illegal to sell for human use without MHRA authorisation. |
| Algeria | Grey Area | No | Unregistered | Same as BPC-157. Not ANPP registered. Import requires drugs to be marketed in country of origin + third country first. |
| Andorra | Grey Area | No | Not Scheduled | Not authorized. Same framework as BPC-157. |
| Angola | Grey Area | No | Unregistered | Same as BPC-157. Not INABEC registered. Major enforcement gaps. |
| Argentina | Grey Area | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Austria | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| Bahrain | Grey Area | No | Unregistered | Not specifically regulated. |
| Bangladesh | Grey Area | No | Not Scheduled | Not registered. Same framework as BPC-157. No local market. |
| Belgium | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| Belize | Grey Area | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Bolivia | Grey Area | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Bonaire | Grey Area | No | Not Scheduled | Same. Not controlled. Unauthorized if for human consumption. |
| Bosnia and Herzegovina | Grey Area | No | Not Scheduled | Non-EU. Not registered. Research-label purchase tolerated. WADA banned. |
| Botswana | Grey Area | No | Unregistered | Same as BPC-157. Not BoMRA registered. Import requires permit. |
| Brazil | Grey Area | No | Unregistered | Same as BPC-157. Not ANVISA approved. Grey area trending restricted. |
| Brunei | Grey Area | No | Not Scheduled | Not registered with BDMCA. Same as BPC-157. Cannot be legally imported as medicinal product. |
| Bulgaria | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| Cambodia | Grey Area | No | Unregistered | Same as BPC-157. Thymosin Beta-4 available through local suppliers. |
| Cameroon | Grey Area | No | Unregistered | Same as BPC-157. Not registered. Import without AOI unauthorized. |
| Canada | Grey Area | No | Not Scheduled (CDSA) | Unauthorized drug. Named in Health Canada seizure notices. Same framework as BPC-157. |
| Cape Verde | Grey Area | No | Unregistered | Same as BPC-157. Not ARFA registered. Simplified Special Import possible with prescription. |
| Chile | Grey Area | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Colombia | Grey Area | No | Unregistered | Same as BPC-157. Available at emerging wellness clinics. |
| Croatia | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| Cyprus | Grey Area | No | Not Scheduled | Not authorized. Same EU framework as BPC-157. No marketing authorization in any EU member state. |
| Czech Republic | Grey Area | No | Not Scheduled / Unauthorized | Same permissive environment as BPC-157. Research vendors operate extensively. |
| Democratic Republic of Congo | Grey Area | No | Unregistered | Same as BPC-157. Not ACOREP registered. |
| Denmark | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| Ecuador | Grey Area | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Egypt | Grey Area | No | Unregistered | Same. Not EDA registered. |
| El Salvador | Grey Area | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Estonia | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| Ethiopia | Grey Area | No | Unregistered | Same as BPC-157. Not EFDA registered. Thymosin Beta-4 not specifically addressed. |
| Fiji | Grey Area | No | Unregistered | Not registered. Same framework as BPC-157. Thymosin Beta-4 not specifically addressed. |
| Finland | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| France | Grey Area | No | Not Scheduled / Unauthorized | Same strict framework. France one of most restrictive EU countries. |
| French Guiana | Grey Area | No | Unauthorized Medicine | French framework. Unauthorized medicine. |
| Georgia | Grey Area | No | Not Scheduled | Non-EU. Not registered. Research-label purchase tolerated. Very weak enforcement environment. |
| Germany | Grey Area | No | Not Scheduled / Unauthorized | Same criminal risk as BPC-157 under AntiDopG. Possession can be prosecuted. |
| Ghana | Grey Area | No | Unregistered | Same as BPC-157. Not registered. Not specifically targeted. |
| Greece | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| Guatemala | Grey Area | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Guyana | Grey Area | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Honduras | Grey Area | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Hong Kong | Grey Area | No | Unregistered Pharmaceutical | Same. Not registered with DH. |
| Hungary | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| Iceland | Grey Area | No | WADA S2 (peptide hormones); unauthorized medicine | Same as BPC-157. WADA S2 classified. Postal import prohibited. Luggage import 30-day max with physician certificate. |
| India | Grey Area | No | Unregistered | Same. India manufactures and exports. Domestically available. |
| Indonesia | Grey Area | No | Unregistered | Same as BPC-157. Bali wellness clinics. |
| Iran | Grey Area | No | Not Scheduled | Not registered. Same as BPC-157. Sanctions limit imports. |
| Iraq | Grey Area | No | Not Scheduled | Not registered. Same weak enforcement framework. Imports may enter through unregulated channels. |
| Ireland | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| Israel | Grey Area | No | Unregistered | Same framework. Not registered. |
| Italy | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| Ivory Coast | Grey Area | No | Unregistered | Same as BPC-157. Not registered. |
| Japan | Grey Area | No | Unapproved Drug | Same as BPC-157. Unapproved under PMD Act. |
| Jordan | Grey Area | No | Unregistered | Not specifically regulated. |
| Kenya | Grey Area | No | Unregistered | Same as BPC-157. Not specifically addressed by PPB. |
| Kuwait | Grey Area | No | Unregistered | Not specifically regulated. |
| Laos | Grey Area | No | Unregistered | Same framework as BPC-157. Not specifically addressed. |
| Latvia | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| Lebanon | Grey Area | No | Not Scheduled | Not registered. Same framework. Crisis has weakened enforcement. |
| Libya | Grey Area | No | Unregistered | Same as BPC-157. Not registered. No drug scheduling system. |
| Liechtenstein | Grey Area | No | Not Scheduled | Not authorized. Same EEA framework as BPC-157. |
| Lithuania | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| Luxembourg | Grey Area | No | Not Scheduled | Not authorized. Same EU framework as BPC-157. |
| Madagascar | Grey Area | No | Unregistered | Same as BPC-157. Not AMM registered. |
| Malawi | Grey Area | No | Unregistered | Same as BPC-157. Not PMRA registered. |
| Malaysia | Grey Area | No | Unregistered | Not specifically regulated. |
| Maldives | Grey Area | No | Unregistered | Not MFDA registered. Same framework as BPC-157. |
| Malta | Grey Area | No | Unauthorized Medicine | Same as BPC-157. Unauthorized under EU pharmaceutical framework. |
| Mauritius | Grey Area | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Mexico | Grey Area | No | Unregistered | Same as BPC-157. Available at wellness clinics. No COFEPRIS approval needed in practice. |
| Monaco | Grey Area | No | Not Scheduled | Not authorized. Same French pharmaceutical framework applies in Monaco. |
| Montenegro | Grey Area | No | Not Scheduled | Non-EU. Not registered. Research-label purchase tolerated. WADA banned. |
| Morocco | Grey Area | No | Unregistered | Same as BPC-157. No AMM. Not specifically regulated but falls under general prohibition on unregistered medicines. |
| Mozambique | Grey Area | No | Unregistered | Same as BPC-157. Not ANARME registered. |
| Myanmar | Grey Area | No | Unregistered | Same as BPC-157. No meaningful enforcement. |
| Namibia | Grey Area | No | Unregistered | Same as BPC-157. Not NMRC registered. |
| Nepal | Grey Area | No | Unregistered | Same framework as BPC-157. Thymosin Beta-4 not specifically categorized. |
| Netherlands | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| Nicaragua | Grey Area | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Nigeria | Grey Area | No | Unregistered | Same as BPC-157. Not NAFDAC registered. Not specifically targeted. |
| North Macedonia | Grey Area | No | Not Scheduled | Non-EU. Not registered. Research-label purchase tolerated. WADA banned. |
| Norway | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| Oman | Grey Area | No | Unregistered | Not specifically regulated. |
| Pakistan | Grey Area | No | Not Scheduled | Not registered with DRAP. Same framework as BPC-157. |
| Panama | Grey Area | No | Unregistered | Same as BPC-157. Available at regenerative medicine clinics. |
| Paraguay | Grey Area | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Peru | Grey Area | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Philippines | Grey Area | No | Unregistered | Not specifically regulated. |
| Poland | Grey Area | No | Not Scheduled / Unauthorized | Same permissive environment. Poland is a source country for European peptide market. |
| Portugal | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| Romania | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| Russia | Grey Area | No | Unregistered | Same. Available from research suppliers. |
| Rwanda | Grey Area | No | Unregistered | Same as BPC-157. Not registered. |
| Saba | Grey Area | No | Not Scheduled | Same. Not controlled. Unauthorized if for human consumption. |
| Saint Barthelemy | Grey Area | No | Unauthorized Medicine | Same French framework. Unauthorized medicine. |
| Saint Martin (French) | Grey Area | No | Unauthorized Medicine | Same French framework. Unauthorized medicine. |
| Senegal | Grey Area | No | Unregistered | Same as BPC-157. Not registered. Personal import requires special authorization. |
| Serbia | Grey Area | No | Not Scheduled | Non-EU. Not registered as medicine. Research-label purchase tolerated. Very low enforcement. |
| Seychelles | Grey Area | No | Unregistered | Same framework as BPC-157. No registration system. |
| Sint Eustatius | Grey Area | No | Not Scheduled | Same. Not controlled. Unauthorized if for human consumption. |
| Sint Maarten | Grey Area | No | Not Scheduled | Same. Not controlled. Unauthorized if for human consumption. |
| Slovakia | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| Slovenia | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| South Africa | Grey Area | No | Unregulated | Same status as BPC-157. Not scheduled. Sold as research chemical by SA vendors. Available at peptide therapy clinics. Not regulated by SAHPRA. WADA prohibited. |
| South Korea | Grey Area | No | Unapproved Drug | Same as BPC-157. Not MFDS approved. |
| Spain | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| Sri Lanka | Grey Area | No | Unregistered | Not NMRA registered. Same framework as BPC-157. |
| Suriname | Grey Area | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Sweden | Grey Area | No | Not Scheduled / Unauthorized | Same. Doping Act applies. Personal use criminalized. |
| Switzerland | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. |
| Taiwan | Grey Area | No | Unapproved Drug | Same. Not TFDA approved. |
| Tanzania | Grey Area | No | Unregistered | Same as BPC-157. Not TMDA registered. Import requires permit. |
| Thailand | Grey Area | No | Unregistered | Same as BPC-157. Available at wellness clinics. |
| Tunisia | Grey Area | No | Unregistered | Same as BPC-157. No MA from DPM. Not specifically regulated but unregistered medicines prohibited. |
| Turkey | Grey Area | No | Unregistered | Same as BPC-157. |
| Uganda | Grey Area | No | Unregistered | Same as BPC-157. Not NDA registered. |
| Ukraine | Grey Area | No | Not Scheduled | Non-EU. Not registered. Research-label purchase tolerated. Enforcement low due to wartime priorities. |
| United States | Grey Area | No | Not Scheduled | Not scheduled. On FDA Category 2 prohibited compounding list. Same enforcement pattern as BPC-157. Legal to possess, illegal to sell for human use. |
| Uruguay | Grey Area | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| US Virgin Islands | Grey Area | No | Not Scheduled | Same as US federal law. FDA Category 2 banned. |
| Venezuela | Grey Area | No | Unregistered | Same as BPC-157. Not specifically regulated. |
| Vietnam | Grey Area | No | Unregistered | Not specifically regulated. |
| Zambia | Grey Area | No | Unregistered | Same as BPC-157. Not ZAMRA registered. |
| Zimbabwe | Grey Area | No | Unregistered | Same as BPC-157. Not MCAZ registered. Import without authorization subject to confiscation. |
| Australia | Prescription | Yes | Schedule 4 + Appendix D Item 5 | Schedule 4 + Appendix D Item 5 effective 1 June 2016. Thymosin Beta-4 specifically listed. |
| New Zealand | Prescription | Yes | Unapproved (Rx Required) | Same as BPC-157. Prescription medicine classification. |
| United Arab Emirates | Prescription | Yes | Clinic Prescribed | Same as BPC-157. Clinic-administered only. |
| China | Banned | No | Unapproved Drug | Same. Manufactured for export but domestic consumer use prohibited. |
| Cuba | Banned | No | State Controlled | State pharmaceutical monopoly via CECMED/BioCubaFarma. No private purchase/import permitted. |
| Qatar | Banned | No | Unauthorized | Same. |
| Saudi Arabia | Banned | No | Unauthorized | Same. Not SFDA registered. |
| Singapore | Banned | No | Unapproved Health Product | Same. HSA unapproved. Do not import to Singapore. |
Data is researcher-verified but not legal advice. Regulations change frequently. Always verify with local authorities before purchasing, importing, or traveling with peptides. Last verified: 2026-02-28.